3-methylcholanthrene has been researched along with Immunologic Deficiency Syndromes in 5 studies
Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.
3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.
Immunologic Deficiency Syndromes: Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Athymic-nude (nu/nu) mice and normal (nu/+) mice showed no differences in either latent period or incidence of local sarcomas or lung adenomas within 120 days after administration of 3-methylcholanthrene at birth." | 3.65 | Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. ( Stutman, O, 1974) |
| "In a prostate cancer model, aggressive tumors arising in NKG2D-deficient mice expressed higher amounts of NKG2D ligands than did similar tumors in wild-type mice, suggesting an NKG2D-dependent immunoediting of tumors in this model." | 1.35 | NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. ( Cado, D; Choy, A; Gallardo, F; Greenberg, NM; Greenberg, NR; Guerra, N; Joncker, NT; Knoblaugh, S; Raulet, DH; Tan, YX; Xiong, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guerra, N | 1 |
| Tan, YX | 1 |
| Joncker, NT | 1 |
| Choy, A | 1 |
| Gallardo, F | 1 |
| Xiong, N | 1 |
| Knoblaugh, S | 1 |
| Cado, D | 1 |
| Greenberg, NM | 1 |
| Greenberg, NR | 1 |
| Raulet, DH | 1 |
| Shearer, WT | 1 |
| Fink, MP | 1 |
| Leibowitz, S | 1 |
| Schwartz, RS | 1 |
| Burnet, FM | 1 |
| Stutman, O | 1 |
3 reviews available for 3-methylcholanthrene and Immunologic Deficiency Syndromes
| Article | Year |
|---|---|
Immune surveillance system: its failure and activation.
Topics: Aged; Animals; Antibodies; Breast Neoplasms; Cell Transformation, Neoplastic; Complement System Prot | 1977 |
Malignancy as a complication of immunosuppressive therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antibody Formation; Antigens, Neoplasm; Breast Neoplasms; Burk | 1971 |
Implications of cancer immunity.
Topics: Animals; Antibody Formation; Antigens, Neoplasm; Cell Membrane; Child; Fetal Proteins; Gastrointesti | 1973 |
2 other studies available for 3-methylcholanthrene and Immunologic Deficiency Syndromes
| Article | Year |
|---|---|
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.
Topics: Adenocarcinoma; Animals; Benz(a)Anthracenes; Disease Models, Animal; Female; Fibrosarcoma; Immunolog | 2008 |
Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice.
Topics: Adenoma; Animals; Female; Fibrosarcoma; Graft Rejection; Immunologic Deficiency Syndromes; Lung Neop | 1974 |